Pharmaceutical Industry News 3 December 2025

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

As of Tuesday, December 9, 2025, Eli Lilly (NYSE: LLY) sits at the center of nearly every conversation about obesity drugs, oncology breakthroughs and “next trillion‑dollar” stocks. The shares trade around $980 per share, down about 1.6% on the day but

9 December 2025

Company News·Investment Insights·Market Forecasts·Pharmaceutical Industry·Stock Analysis

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. (NASDAQ: DYN) shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In

9 December 2025

Biotech News·Financial Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering

9 December 2025

Biotechnology·Healthcare News·Investment·Pharmaceutical Industry·Stock Market

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after

9 December 2025

Analyst Forecasts·Biotechnology·Pharmaceutical Industry·Stock News

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about

9 December 2025

Biotechnology·Investment News·Pharmaceutical Industry·Stock Market

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high

8 December 2025

Biotech News·Investing·Pharmaceutical Industry·Stock Market

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor

8 December 2025

Analyst Insights·Biotechnology·Investment News·Pharmaceutical Industry·Stock Market

AbbVie Stock (ABBV) Today: Price, Dividend Hike, Pipeline Catalysts and 2025–2026 Outlook

AbbVie’s stock is trading just below record highs as investors digest a powerful mix of rising earnings, a fresh dividend increase and a steady drumbeat of positive pipeline news in immunology, neuroscience and oncology. As of the close on Friday,

7 December 2025

Dividend Investing·Financial Analysis·Investment Strategies·Pharmaceutical Industry·Stock Market

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer Inc. (NYSE: PFE) is ending 2025 in better shape than it started, but investors are still debating whether the stock is a high‑yield value opportunity or a classic “value trap.” As of Friday, December 5, 2025, Pfizer shares closed

6 December 2025

Company News·Financial Forecasts·Investment Analysis·Pharmaceutical Industry·Stock Market

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and

5 December 2025

Biotech Stocks·FDA Approvals·Investment News·Pharmaceutical Industry

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares

4 December 2025

Biotech News·Financial Updates·Investment Insights·Pharmaceutical Industry·Stock Market

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints. GlobeNewswire Below is a

3 December 2025

Biotechnology·Clinical Trials·Investment Analysis·Pharmaceutical Industry·Stock Market

Pharmaceutical Industry News 3 December 2025 - 9 December 2025